dual gip and glp-1 receptor agonist GIP/GLP-1 agonists: New advances for treating type-2 diabetes PDF] Novel dual GLP-1/GIP receptor

Liraglutide (Saxenda): Liraglutide is part of a comprehensive weight management program, administered through daily injections

454 By reducing MMP expression, GLP-1R stimulation may help preserve the integrity of fibrous caps and mitigate the risk of plaque rupture

Liraglutide (Saxenda, Victoza) Liraglutide was originally approved to treat diabetes

As in the case of the injectable GLP-1RAs, these side effects were generally mild to moderate and occurred during dose escalation and were generally transient and mitigated by gradual dose escalation

130,133 In the gastrointestinal tract, it lowers the synthesis and secretion of triglycerides